Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Transl Oncol ; 10(4): 241-5, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18411200

ABSTRACT

Lytic and blastic lesions have been associated to malignant tumours, such as solid cancer (breast cancer, renal cancer, prostate cancer, malignant melanoma or thyroid tumours). Although a mixed pattern with lytic and blastic lesions is due to metastatic tumour, this is not the only possible origin. The following case shows a systematic. This case report shows the number of tests that were made in order to discover the origin of osteolytic and osteoblastic lesions and it is notable that there is not an occult neoplasia on every occasion.


Subject(s)
Bone Neoplasms/secondary , Mastocytosis, Systemic/diagnosis , Mastocytosis, Systemic/physiopathology , Osteolysis/etiology , Aged , Anemia/complications , Back Pain/etiology , Bone Density Conservation Agents/therapeutic use , Diagnosis, Differential , Diphosphonates/therapeutic use , Female , Humans , Hypertension/complications , Imidazoles/therapeutic use , Immunologic Factors/therapeutic use , Interferon-alpha/therapeutic use , Magnetic Resonance Imaging , Mastocytosis, Systemic/drug therapy , Osteolysis/drug therapy , Osteoporosis/complications , Osteoporosis/drug therapy , Radionuclide Imaging , Zoledronic Acid
2.
AIDS Patient Care STDS ; 19(7): 421-4, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16053398

ABSTRACT

Concern exists about the risk of nephrotoxicity using tenofovir (TDF) in HIV-infected patients. We performed a retrospective case-control study including 122 consecutive TDF-naive patients who started treatment with TDF-containing regimens and 194 patients receiving antiretroviral therapy with other antiretroviral drugs. During a 12-month observation period 5 (4.1%) patients in the TDF group versus 1 (0.5%) in the control group developed grade 1 or higher serum creatinine elevations (p = 0.018). Only 2 (1.6%) patients discontinued TDF treatment as a result of serum creatinine level elevations. In 4 of the 5 patients developing creatinine elevations TDF was combined with lopinavir-ritonavir. The use of TDF in clinical practice during a 12-month period is associated with low risk of mild renal failure. Further studies to assess long-term renal safety of this drug are needed.


Subject(s)
Adenine/analogs & derivatives , HIV Infections/drug therapy , Kidney Diseases/chemically induced , Organophosphonates/adverse effects , Reverse Transcriptase Inhibitors/adverse effects , Adenine/adverse effects , Adenine/therapeutic use , Antiretroviral Therapy, Highly Active/adverse effects , Antiretroviral Therapy, Highly Active/methods , Case-Control Studies , Creatinine/analysis , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , HIV Infections/diagnosis , Humans , Incidence , Kidney/drug effects , Kidney Diseases/epidemiology , Kidney Function Tests , Male , Organophosphonates/therapeutic use , Probability , Prognosis , Reference Values , Retrospective Studies , Reverse Transcriptase Inhibitors/therapeutic use , Risk Assessment , Severity of Illness Index , Tenofovir
SELECTION OF CITATIONS
SEARCH DETAIL
...